BerlexYasmin Reps Likely To Promote Anti-Fluid, Androgen Effects
Executive Summary
Sales reps will likely detail Yasmin by promoting its anti-fluid-retention and anti-androgen effects when the oral contraceptive becomes available in mid-June.
You may also be interested in...
Berlex Yasmin 20 NDA Filing For Lower Estrogen Dose Slated For Q4
Schering AG's Berlex subsidiary will highlight Yasmin 20's lower estrogen dose and 24-day hormone treatment regimen in marketing the oral contraceptive
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011